[Retrospective comprehensive assessment of the treatment effect of children with growth hormone deficiency].
The most often cause of hormonal microsomy is a growth hormone deficit on the consequence of hypofuncion of the pituitary anterior lobe (SNP). The aim of the study was a retrospective analysis of children with SNP treated with a synthetic growth hormone (rhGH). Analyzed was the growth velocity in dependence of the dose and developmental period of the patients. Additional analyzed was the influence of the relative body mass (BMI) index and the degree of growth hormone deficit on the result of the therapy with the recombined growth hormone. Analyzed was also the maturity of the bone age during the therapy with growth hormone. A statistical analysis was performed of the influence of the particular parameters on the growth velocity of the investigated patients on support on the one - or multifunctional variant analysis MANOVA. Observed was, that the growth velocity was the highest in children treated with the highest dose of growth hormone. A dependence between the degree of growth hormone deficit and the growth velocity during the therapy with growth hormone was not evidenced. Not shown was also difference in the growth velocity in dependence on the body mass index. Bone age after the therapy during the three years do not achieve the calendar age in the investigated children. The comparison of the therapeutic results in children in a different phase of maturity shows that the best growth velocity was achieved in children in whom the therapy was started before the age of six years. Therefore the beginning of the therapy with growth hormone was recommended at the earliest. The performed examination evidenced also, that children treated with present doses of growth hormone do not attain the provided height, therefore necessary is a further optimalisation of the therapy of SNP with higher doses of rhGH.
Kostecka
Lidia
L
Klinika Endokrynologii i Diabetologii Wieku Rozwojowego AM we Wrocławiu, Wrocław.
Wasikowa
Renata
R
D000293:Adolescent; D001827:Body Height / Q000187:drug effects*; D015519:Bone Density / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000172:deficiency; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy*; D008297:Male; D012189:Retrospective Studies
D019382:Human Growth Hormone; D013006:Growth Hormone